Cerveau Technologies Inc. has agreed to supply one of its investigational imaging agents for use in neurodegenerative disease research studies overseen by Ionis Pharmaceuticals Inc., as part of a research collaboration agreement.
Used in PET scans, [F-18]MK-6240 is designed to evaluate the status and progression of neurofibrillary tangles (NFTs), which consist of aggregated tau protein in the brain, a hallmark of Alzheimer’s disease and other neurodegenerative conditions.
“We are thrilled by the opportunity to work with Ionis to foster development of this exciting technology,” Rick Hiatt, president and CEO of Cerveau Technologies, said in a statement. “Consistent with our vision, we will make novel imaging biomarkers and supporting informatics available to our pharmaceutical industry and academic partners, providing access to the broader scientific community.”
News of the partnership builds upon Cerveau’s recent decision to branch out
its production network to six new U.S. locations to enhance access to and opportunities for research on [F-18]MK-6240, as well as another agreement
with Kobe Hospital in Japan for multiple studies on the use of the agent.
The two plan to assess the effect of the [F-18]MK-6240 as a biomarker as part of a collaboration focused on the use of therapies and their impact on the progression of neurodegenerative diseases in humans, such as Alzheimer’s.
“There is a critical need for sensitive biomarkers for early in-life diagnosis of neurodegenerative diseases to allow for more appropriate staging of disease states, and measuring the effect of disease-modifying therapeutics,” Frank Bennett, SVP research of Ionis Pharmaceuticals, said in a statement. “Imaging agents such as [F-18]MK-6240 are important tools for accelerating the development of our disease modifying antisense therapies.”
Derived as a collaboration between Enigma Biomedical Group Inc. and Sinotau Pharmaceutical Group, Cerveau aims to develop diagnostics and technology for patients suffering from neurodegenerative diseases such as Alzheimer’s.
An RNA-targeted drug discovery and development enterprise, Ionis focuses on developing pharmaceuticals for patients with the highest unmet medical needs, including those with severe and rare diseases.
Cerveau and Ionis did not respond for comment.